Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

Caspofungin (CAS) as salvage therapy for refractory invasive aspergillosis (IA) had a response rate of 45% among a heterogeneous group of patients. The use of CAS with other agents is appealing given its unique mechanism of action. Therefore, the authors retrospectively evaluated the efficacy and toxicity of CAS plus liposomal amphotericin B (LipoAMB) in patients with documented (definite or probable) or possible IA.

[1]  K. Sepkowitz,et al.  Refractory Aspergillus pneumonia in patients with acute leukemia , 2003, Cancer.

[2]  G. Nitenberg,et al.  Voriconazole versus amphotericin B for invasive aspergillosis. , 2002, The New England journal of medicine.

[3]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[4]  T. Patterson,et al.  Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis , 2002, Antimicrobial Agents and Chemotherapy.

[5]  B. Cahill,et al.  Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  D. Kontoyiannis,et al.  Invasive Aspergillosis in 2002: An Update , 2002, European Journal of Clinical Microbiology and Infectious Diseases.

[7]  E. Thiel,et al.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Rex,et al.  In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp , 2002, Antimicrobial Agents and Chemotherapy.

[9]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Kontoyiannis.  A Clinical Perspective for the Management of Invasive Fungal Infections: Focus on IDSA Guidelines , 2001, Pharmacotherapy.

[11]  A. Groll,et al.  Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections , 2001, Expert opinion on investigational drugs.

[12]  D. Kontoyiannis,et al.  Rationale for Combination Antifungal Therapy , 2001, Pharmacotherapy.

[13]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[15]  D. Kontoyiannis,et al.  Invasive aspergillosis (IA) in patients with leukemia and bone marrow transplant patients (PTS): Poor outcome despite aggressive therapy , 2000 .

[16]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[17]  T J Walsh,et al.  Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Denning,et al.  Practice Guidelines for Diseases Caused by Aspergillus , 2000 .

[19]  D. Denning,et al.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Armstrong,et al.  Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. , 1999, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[21]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[22]  D. Denning,et al.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. , 1990, Reviews of infectious diseases.